Femasys (NASDAQ:FEMY) Announces Quarterly Earnings Results

Femasys (NASDAQ:FEMY) issued its quarterly earnings data on Friday. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.07, Zacks reports. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.62 million. Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%.

Femasys Price Performance

Shares of NASDAQ:FEMY traded up $0.02 during midday trading on Friday, hitting $1.42. The company’s stock had a trading volume of 52,887 shares, compared to its average volume of 101,624. The business’s 50 day simple moving average is $1.96 and its 200 day simple moving average is $5.62. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.55 and a current ratio of 2.14. The company has a market cap of $11.90 million, a P/E ratio of -0.40 and a beta of -2.13. Femasys has a 12-month low of $1.25 and a 12-month high of $20.80.

Wall Street Analysts Forecast Growth

FEMY has been the subject of several research analyst reports. Lake Street Capital reduced their target price on Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Wall Street Zen cut shares of Femasys from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 8th. Maxim Group decreased their price objective on shares of Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Weiss Ratings lowered shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Femasys Company Profile

Femasys Inc. is a medical technology company focused on developing and commercializing products for women’s health, with an emphasis on fertility and contraception. Founded in 2004 and headquartered in Georgia, the company aims to provide minimally invasive options for reproductive care. Its products include FemVue, a system used with ultrasound to evaluate whether a woman’s fallopian tubes are open, and FemaSeed, a device designed to deliver sperm closer to the site of fertilization during insemination.